Is DRRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

743 people get DRRX articles and Market Currents by email alert.

Get email alerts on DRRX »

HEADLINES:

FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
DURECT Announces Update on Remoxy®

PR Newswire (May 10, 2013)
Durect: Pfizer Hints At Progress With Remoxy
PropThink • Fri, May 3 • 11 Comments
DURECT Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs

PR Newswire (May 2, 2013)
Pfizer's Efforts Boost Pain Therapeutics And Durect Corp.
Bob's Stocks • Thu, May 2 • 9 Comments
Why Did Pain Therapeutics Increase Over 25%?
C.R. Jackson • Thu, May 2 • 35 Comments
DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call

PR Newswire (Apr 24, 2013)
DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)

PR Newswire (Apr 16, 2013)
3 Companies Aiming For The $1.2B Opioid Addiction Market
Healthcare Specialist • Sun, Apr 7 • 29 Comments
Durect Corporation And Pain Therapeutics Big Gainers For 2013?
Bob's Stocks • Thu, Mar 21 • 7 Comments
AcelRx Pharmaceutical's Potential Billion-Dollar Treatment Under The Radar
Scott Matusow • Tue, Mar 19 • 19 Comments
A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships
Craig Keolanui • Mon, Mar 18 • 2 Comments
3 Biotech Stocks Ready To Rally
BuySellShort • Wed, Mar 6 • 8 Comments
For Durect Investors, Cash And Revenues Limit Downside
PropThink • Mon, Mar 4 • 5 Comments
DURECT's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of Programs

PR Newswire (Feb 28, 2013)
Durect Offers 2 Shots On Goal, Almost 100% Upside
PropThink • Tue, Feb 26
DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call

PR Newswire (Feb 22, 2013)
All You Need To Know About Remoxy
Basileus • Mon, Feb 18 • 8 Comments

To learn more about Seeking Alpha Pro, click here.

Durect: Pfizer Hints At Progress With Remoxy
PropThink • Fri, May 3 • 11 Comments
For Durect Investors, Cash And Revenues Limit Downside
PropThink • Mon, Mar 4 • 5 Comments
Durect Offers 2 Shots On Goal, Almost 100% Upside
PropThink • Tue, Feb 26
Durect Corporation - Insider Activity Report
Jorge Aura • Tue, Nov 20, 2012 • 4 Comments
Buy Durect As Visibility On Remoxy Improves
Jason Napodano • Tue, Sep 11, 2012 • 5 Comments
Durect Corporation - A Unique & Undervalued Biopharma Development Company
Kyle Walker • Thu, Aug 30, 2012 • 9 Comments
3 Reasons To Buy Durect Corporation
Markus Aarnio • Fri, Jun 29, 2012 • 4 Comments
Durect: Be Patient Investors, Better Times Are Ahead
Zacks Investment Research • Wed, Jun 17, 2009
Durect Shares Up 20% On Painkiller Deal
SA Editor Jonathan Liss • Fri, Dec 1, 2006
Painkiller Deal Good News for Durect Corp.
H.S. Ayoub • Fri, Dec 1, 2006

FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
Pfizer's Efforts Boost Pain Therapeutics And Durect Corp.
Bob's Stocks • Thu, May 2 • 9 Comments
Why Did Pain Therapeutics Increase Over 25%?
C.R. Jackson • Thu, May 2 • 35 Comments
3 Companies Aiming For The $1.2B Opioid Addiction Market
Healthcare Specialist • Sun, Apr 7 • 29 Comments
Durect Corporation And Pain Therapeutics Big Gainers For 2013?
Bob's Stocks • Thu, Mar 21 • 7 Comments
AcelRx Pharmaceutical's Potential Billion-Dollar Treatment Under The Radar
Scott Matusow • Tue, Mar 19 • 19 Comments
A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships
Craig Keolanui • Mon, Mar 18 • 2 Comments
3 Biotech Stocks Ready To Rally
BuySellShort • Wed, Mar 6 • 8 Comments
All You Need To Know About Remoxy
Basileus • Mon, Feb 18 • 8 Comments
Small Pharmaceuticals With Near Term Catalysts - Durect And Inovio
BuySellShort • Mon, Feb 4 • 11 Comments
Imminent Catalysts Should Keep Investor Interest Alive For These Pharmaceuticals - Part II
Chemistfrog • Mon, Feb 4 • 9 Comments
BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug
Scott Matusow • Tue, Jan 15 • 23 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
Is Zogenix A Buy After FDA Panel Says 'No' To Zohydro?
C.R. Jackson • Fri, Dec 14, 2012 • 15 Comments
Pain Therapeutics - Another Oxycodone Remix
Suresh Gupta • Tue, Oct 23, 2012 • 3 Comments
5 Healthcare Stocks With Healthy Long-Term Debt Ratios And Hearty Profitability
ZetaKap • Thu, Oct 11, 2012 • 3 Comments
3 Best Biotech Stocks For This Week (Part V)
Jorge Aura • Mon, Oct 8, 2012 • 2 Comments
5 Healthcare Companies With Insider Buying Filed On August 24 - 28
Markus Aarnio • Wed, Aug 29, 2012 • 2 Comments
3 Drugmakers Deeply Undervalued By The Graham Number
Kapitall • Thu, Jul 19, 2012
AcelRx Pharmaceuticals: Next Generation Of Pain Management Technologies
LifeSci Advisors • Mon, Jul 16, 2012 • 7 Comments

DURECT Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
DURECT's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
DURECT Corporation Q1 2010 Earnings Call Transcript
Tue, May 11, 2010
DURECT Corporation Q1 2009 Earnings Call Transcript
Wed, May 6, 2009
DURECT Corporation, Q4 2008 Earnings Call Transcript
Mon, Feb 9, 2009
DURECT Corporation Q3 2008 Earnings Call Transcript
Thu, Nov 20, 2008
DURECT Corporation Q2 2008 Earnings Call Transcript
Sun, Sep 14, 2008
DURECT Corporation Q1 2008 Earnings Call Transcript
Mon, May 26, 2008
DURECT Corp Q4 2007 Earnings Call Transcript
Mon, Feb 18, 2008

DURECT Announces Update on Remoxy®

PR Newswire (May 10, 2013)
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs

PR Newswire (May 2, 2013)
DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call

PR Newswire (Apr 24, 2013)
DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)

PR Newswire (Apr 16, 2013)
DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of Programs

PR Newswire (Feb 28, 2013)
DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call

PR Newswire (Feb 22, 2013)
DURECT to Participate in Upcoming Healthcare Conferences

PR Newswire (Feb 5, 2013)
DURECT Announces Positive Results from Relday™ Phase 1 Clinical Trial

PR Newswire (Jan 3, 2013)
DURECT Announces Pricing of Public Offering of Common Stock

PR Newswire (Dec 6, 2012)
DURECT to Participate in Upcoming Healthcare Conferences

PR Newswire (Nov 13, 2012)
DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs

PR Newswire (Nov 5, 2012)
DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call

PR Newswire (Oct 30, 2012)
DURECT to Participate in Upcoming Healthcare Conferences

PR Newswire (Aug 21, 2012)
DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs

PR Newswire (Aug 6, 2012)
DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative Analgesia

PR Newswire (Aug 6, 2012)
DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference Call

PR Newswire (Jul 26, 2012)
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs

PR Newswire (May 3, 2012)
DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology

PR Newswire (May 3, 2012)
DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call

PR Newswire (Apr 25, 2012)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Jan 6, 2012)

DRRX vs. ETF Alternatives

Company Description

Currently, there's no company description for DRRX.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 12:52 PM Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move]
Friday, May 10, 8:29 AM The sell-off in shares of Durect (DRRX) has accelerated meaningfully as the stock is now down 37% premarket after Pfizer's Remoxy comments. Reminder: DRRX is entitled to royalties of between 6% and 11.5% of potential Remoxy net sales which some analysts have said could ultimately hit $1B if the drug reaches market. The impact for DRRX, which only had $53.1M in total revenue in 2012, really cannot be overstated. See SA contributor PropThink's recent analysis for more. (Also: PTIE crashes on PFE comments) 1 Comment [Healthcare, On the Move]
Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
Friday, May 3, 6:49 AM Durect (DRRX): Q1 EPS of -$0.05 beats by $0.02. Revenue of $4.2M beats by $0.33M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
Tuesday, April 16, 7:51 AM Durect (DRRX) submits NDA for POSIDUR, a non-opioid, long-acting local anesthetic for the treatment of post-surgical pain. The company, which is also developing an abuse-resistant form of oxycodone, notes that non-opioid options for the management of pain post-surgery can hasten recovery and shorten hospital stays.
Comment! [Healthcare]
Monday, March 25, 9:20 AM Durect (DRRX) started at Buy at Stifel Nicolaus, price target $3. 1 Comment [Healthcare]
Thursday, February 28, 5:24 PM Durect (DRRX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $3.26M misses by $1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 3, 8:45 AM Zogenix (ZGNX) +5.8% after saying its Relday treatment for schizophrenia had a good safety and PK (pharmacokinetic - what the body does to the drug) profile in a Phase I study, which will now be extended for increased doses. Durect (DRRX) is also on watch, as Zogenix has licensed Durect's technology for use in Relday. (PR) Comment! [Healthcare, On the Move]
Thursday, November 1, 2012, 12:45 PM Midday top 10 gainers: HGSH +78%. WMCO +41%. KSWS +35%. CHC +32%. REDF +26%. GTIV +23%. WNC +22%. IMH +20%. JDAS +17%. NEWP +16%. Midday top 10 Losers: CMVT -48%. DRRX -39%. PTIE -30%. ABMD -30%. FARO -18%. AAWW -17%. FBN -16%. GBX -14%. ZUMZ -14%. EONC -14%. Comment!
Monday, August 6, 2012, 4:26 PM Durect (DRRX): Q2 EPS of $0.05 in-line. Revenue of $4.8M misses by $1M. Shares +1.6% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Thursday, January 5, 2012, 5:58 PM Durect (DRRX) drops 46.6% AH after stating Phase III trial results for its Posidur post-operative pain-relief drug "did not reach statistical significance." The company says it will now "hold a pre-NDA meeting with the FDA" to discuss the results. (previously) Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 3:54 PM Pain Therapeutics (PTIE -24.7%) is Nasdaq's leading loser for the second straight session, adding to Friday's 40%-plus drop after the FDA rejected a new drug application for Remoxy, its extended release capsules of oxycodone developed with Pfizer (PFE +0.4%). Durect (DRRX -8.5%), whose technology was used to develop the drug, also adds to losses. Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 9:10 AM Premarket gainers: CNU +32%. LDK +6%. ACUR +6%. ZLCS +5%. SGMO +4%. ALU +3%. SINA +3%. ERIC +3%. ASML +3%.
Losers: PTIE -29%. DRRX -16%. XCO -4%. CTIC -3%. RDN -3%. Comment! [On the Move]
Friday, June 24, 2011, 11:11 AM Durect (DRRX -28%) is another casualty of the FDA's rejection of Remoxy. Its technology - designed to discourage common methods of tampering - was used to develop the drug. PTIE -37%, PFE -1.5%. Comment! [Healthcare, On the Move]

Red Acre Investments
Take our poll about $PFE and Remoxy $DRRX and $PTIE investors too! http://bit.ly/14k2VHo
Apr 24, 12:39 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
Binary Event Watch April 2013 - Part II http://bit.ly/114CVMl ... $RPTP $AVEO $DCTH $VVUS $SRPT $PFE $DRRX $PTIE $TTNP $XNPT $EXAS
Apr 12, 12:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
April binary event watch pt2 $PFE $RPTP $TTNP $AVEO $DCTH $PFE $SRPT $VVUS $AGN $DRRX $PTIE $XNPT $EXAS get it free: http://bit.ly/10SbDco
Apr 11, 7:03 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joe kelly
$DRRX man this stock gets no attention.
Jan 9, 1:39 PM
Reply (2)

• !Report Abuse
View all 2 replies
Valens29: Sure doesn't, unfortunately...
Jan 14, 11:57 PM
• !Report Abuse
joe kelly: Hey. I just saw Scott Matusaw mention DRRX in a sentence in his latest article. We're on our way.
Jan 15, 8:57 AM
• !Report Abuse
Add a reply...

140 characters

ZetaKap
5 Healthcare Stocks With Healthy Long-Term Debt Ratios And Hearty Profitability http://bit.ly/Q30yOc $DRRX $KH $MD $VAR $YDNT @ZetaKap
10/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jay094
I don't understand why DRRX shares got beat-up yesterday and only up .04 cents today.
8/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jay094
Ok, I sold out of my (TGS) shares and bought (DRRX) order executed at .91 cents per share. Right now thinking about buying more (SAPX).
8/6/12
Reply (1)

• !Report Abuse
View all 1 replies
joe kelly: Well done. I think DRRX is a great long term buy. Like BDSI was.
8/6/12
• !Report Abuse
Add a reply...

140 characters

texastrucker
I think the financial mess in Europe is having a bad effect on DRRX,but I do think it will be in dollar-land soon.
6/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

texastrucker
DRRX is on a uptrend right know,lets see what the charts say.
6/8/12
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Excited about DRRX. Bought a boatload last week.
6/8/12
• !Report Abuse
texastrucker: sold,walked away with a nice profit DRRX is starting to show weakness unless some insider buys more it might surprise me.
7/8/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Really? ThinkEquity gives Durect (DRRX) a $3 buy target. Stock is only $0.82. But company does have plenty of cash. http://bit.ly/GPHui9
3/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

joe kelly
$DRRX man this stock gets no attention.
Jan 9, 1:39 PM
Reply (2)

• !Report Abuse
View all 2 replies
Valens29: Sure doesn't, unfortunately...
Jan 14, 11:57 PM
• !Report Abuse
joe kelly: Hey. I just saw Scott Matusaw mention DRRX in a sentence in his latest article. We're on our way.
Jan 15, 8:57 AM
• !Report Abuse
Add a reply...

140 characters

Jay094
Ok, I sold out of my (TGS) shares and bought (DRRX) order executed at .91 cents per share. Right now thinking about buying more (SAPX).
8/6/12
Reply (1)

• !Report Abuse
View all 1 replies
joe kelly: Well done. I think DRRX is a great long term buy. Like BDSI was.
8/6/12
• !Report Abuse
Add a reply...

140 characters

texastrucker
DRRX is on a uptrend right know,lets see what the charts say.
6/8/12
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Excited about DRRX. Bought a boatload last week.
6/8/12
• !Report Abuse
texastrucker: sold,walked away with a nice profit DRRX is starting to show weakness unless some insider buys more it might surprise me.
7/8/12
• !Report Abuse
Add a reply...

140 characters

DRRX Durect Corporation

DRRX

Durect Corporation